373 Inverness Parkway, Suite 206
103 articles with Aytu BioScience
Aytu BioScience to Report Fourth Quarter and Full Year Fiscal 2020 Results and Provide Business Update on Tuesday, October 6, 2020
Aytu BioScience, Inc. (NASDAQ:AYTU) announced today that the Company will present its operational results for the fiscal fourth quarter and year ended June 30, 2020 on October 6, 2020, at 4:30 p.m. ET.
Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that it will reschedule its fourth quarter and FY 2020 conference call, previously scheduled for Thursday, September 24 at 4:30pm ET.
Aytu BioScience to Report Fourth Quarter FY 2020 Results and Business Update on Thursday, September 24, 2020
Live Conference Call and Webcast at 4:30 ET
Aytu BioScience Announces Global Agreement to Distribute Pinnacle IVD Corporation's 15-Minute COVID-19 Antigen Test
Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced that the Company has signed an agreement to distribute the Pinnacle CovID RAD Rapid Antigen Detection Test worldwide.
Aytu BioScience COVID-19 IgG/IgM Rapid Test Distribution Partner Apollo Med Innovations Initiates Nationwide Mobile Testing Partnership with Olympus Health and Performance
Aytu BioScience Announces Manufacture and Delivery of Healight(TM) Devices for Use in COVID-19 Clinical Study
Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs, today announced the delivery of Healight™ investigational devices
Aytu BioScience Announces Regulatory Approval of ZolpiMist(R) by Australian Therapeutic Goods Administration
Aytu BioScience today announced the approval of ZolpiMist® (zolpidem tartrate oral spray) by the Therapeutic Goods Administration (TGA) in Australia.
COVID-19 IgG/IgM Rapid Test Cassette Distributed by Aytu BioScience Featured in Business Insider Article
Article Reports Results from Independent Study Demonstrating Test's 100% Sensitivity and Specificity for IgM Antibodies and 96.7% and 97.5% Sensitivity and Specificity, Respectively, for IgG Antibodies
Commercial Partner Acerus Pharmaceuticals Launches Specialty Sales Team Calling on Urologists and Endocrinologists in the United States
Aytu BioScience Announces Distribution Partnership with Apollo Med Innovations to Expand Distribution of COVID-19 IgG/IgM Rapid Test in United States
Apollo Med Innovations Introduces Novel Research-Based Testing Approach to Offer COVID-19 Antibody Testing to Nationwide Network of Over 1,000 Medical Clinics and Recently Launched Mobile Testing Platform ENGLEWOOD, CO / ACCESSWIRE / July 10, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company (the "Company") focused on commercializing novel products that address significant patient needs announced today that the Company has signed a distribution agreeme
Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel products that address significant medical needs, announced the U.S. Food and Drug Administration has granted Emergency Use Authorization for the COVID-19 IgG/IgM Rapid Test Cassette distributed by the Company.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
Expanded U.S. NATETSO® Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational
Closing conditions waived - Amended & Restated Partnership Agreement is now closed
Cerecor Inc. announced that it has closed the sale of its pediatric portfolio of assets with AYTU BioScience, Inc. in a deal valued in excess of $43 million including the assumption of various liabilities and product-related obligations.
Cerecor Inc. announced that it has entered into an asset purchase agreement with AYTU BioScience, Inc. to sell Cerecor’s Pediatric Portfolio in a deal valued in excess of $32 million.
Aytu BioScience, Inc. (NASDAQ: AYTU), and Innovus Pharmaceuticals, Inc. (OTCQB: INNV), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, today announced that the companies have signed a definitive merger agreemen
Acerus Pharmaceuticals Corporation announced that it will be taking an expanded role in the commercialization of NATESTO® in the U.S. The company has entered into an amended and restated licensing agreement with Aytu BioScience, Inc.
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
It was reported today that U.S.-based Merck & Co. will lower the price of some of its drug. It appears to be rippling through the industry, largely in an attempt to stay out of the way of Trump’s attack-tweets.
President Trump was able to declare a small victory in the arena of drug pricing earlier this week when Pfizer opted to delay its second price-hike of the year. Other companies though have not followed suit and have gone through with price increases for their drugs.